報價延遲最少15分鐘:2025/09/16 05:45 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.79
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.01/0.96
|
|
企業價值
5.39B
|
| 資產負債 |
|
每股賬面淨值
-0.36
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
2.79B
|
|
每股收益
7.36
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/16 05:45 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities. |
